Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 14/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15347556 | 0.81 | NAPEPLD (0.52) | NAPEPLDACACBACACA | |
| SCHEMBL30076931 | 0.81 | NAPEPLD (0.52) | NAPEPLDACACBACACA | |
| SCHEMBL17523565 | 0.78 | NAPEPLD (0.48) | NAPEPLDPIM1CHRM1ACACBACACA | |
| SCHEMBL12685120 | 0.77 | NAPEPLD (0.49) | NAPEPLD | |
| SCHEMBL30076917 | 0.77 | NAPEPLD (0.49) | NAPEPLD | |
| SCHEMBL19222497 | 0.77 | NAPEPLD (0.43) | NAPEPLDPIM1CHRM1ACACBACACA | |
| SCHEMBL15347593 | 0.77 | HTR4 (0.44) | NAPEPLDHTR4 | |
| SCHEMBL30077153 | 0.77 | HTR4 (0.44) | NAPEPLDHTR4 | |
| SCHEMBL12685237 | 0.76 | NAPEPLD (0.48) | NAPEPLDPIM1ACACBACACA | |
| SCHEMBL30077109 | 0.76 | NAPEPLD (0.48) | NAPEPLDPIM1ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348577-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LLC (US) | 2022-11-03 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-10155761-B2 | CXCR4 receptor antagonists | PROXIMAGEN, LLC (US) | 2018-12-18 | — | — | US | disclosed |
| EP-2927224-B1 | Receptor antagonists | PROXIMAGEN LTD (GB) | 2018-10-03 | — | — | EP | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| EP-2927224-A1 | Receptor antagonists | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2627649-B1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| EP-2627649-B1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20130289020-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| WO-2012049277-A1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226106-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | NAPEPLD 2860/4885PIM1 2753/4885CHRM1 336/4885 |
| US-20220348577-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | NAPEPLD 2860/4885PIM1 2753/4885CHRM1 336/4885 |
| US-20130289020-A1 | CXCR4 Receptor Antagonists | CXCR4, ACKR3, CXCR1 | NAPEPLD 2243/4885PIM1 2351/4885CHRM1 1577/4885 |
| US-10155761-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | NAPEPLD 2860/4885PIM1 2753/4885CHRM1 336/4885 |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | NAPEPLD 2860/4885PIM1 2753/4885CHRM1 336/4885 |
| US-10995091-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | NAPEPLD 2860/4885PIM1 2753/4885CHRM1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.